Literature DB >> 15076140

Adoptive transfer of anti-idiotypic T cells cure mice of disseminated B cell lymphoma.

Anne C Armstrong1, Said Dermime, Kate Mulryan, Peter L Stern, Tapan Bhattacharyya, Robert E Hawkins.   

Abstract

There is extensive interest in idiotypic vaccination as a treatment of lymphoma. An alternative approach is the adoptive transfer of in vitro generated T cells. This strategy has been used to treat posttransplantation EBV-related diseases. The ability to generate in vitro T cells to peptides derived from immunoglobulin idiotypes raises the possibility of directly using such cells as a treatment of lymphoma. Investigating the adoptive transfer of specific T cells to idiotype derived peptides in a murine lymphoma model is therefore an important part of the clinical translation of this alternative approach. We have generated an idiotype-specific T cell line, able to recognise a defined, naturally processed idiotype-derived epitope. This line has been used to successfully treat mice with disseminated lymphoma supporting the clinical use of idiotype specific T cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15076140     DOI: 10.1097/00002371-200405000-00007

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  2 in total

1.  Controlled major histocompatibility complex-T cell receptor signaling allows efficient generation of functional, antigen-specific CD8+ T cells from embryonic stem cells and thymic progenitors.

Authors:  Jian Lin; Hui Nie; Phillip W Tucker; Krishnendu Roy
Journal:  Tissue Eng Part A       Date:  2010-09       Impact factor: 3.845

2.  CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.

Authors:  Lena M Kranz; Matthias Birtel; Lina Hilscher; Christian Grunwitz; Jutta Petschenka; Fulvia Vascotto; Mathias Vormehr; Ralf-Holger Voss; Sebastian Kreiter; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2016-07-19       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.